Analyst firm TD Cowen issued buy ratings for Molecular Partners, a company based in Switzerland.
2 reports, 1 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst firm TD Cowen issued buy ratings for Molecular Partners, a company based in Switzerland.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Molecular Partners
biopharmaceutical company based in Zürich, Switzerland
Nothing else this week.
-
Switzerland
country in Central Europe
Related events
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- TD Cowen restated a 'buy' rating on Affiliated Managers Group (AMG) on June 6, 2026.
- TD Cowen and Needham & Company provided a buy rating and raised the price objective for Establishment Labs Holdings Inc.
- MarketBeat reported that TD Cowen increased its price objective and gave a buy rating for an unnamed company.
- TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.